Genenta Science S.p.A. (GNTA) vs Tevogen (TVGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Genenta Science S.p.A. (GNTA) has outperformed Tevogen (TVGN) over the past year, losing 78.4% versus a loss of 80.5%. Tevogen is the larger company by market cap ($46.0 million vs $34.2 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GNTA | TVGN |
|---|---|---|
| Share price | $0.7101 | $7.06 |
| Market cap | $34.24M | $45.97M |
| 1-day change | -5.95% | +8.78% |
| YTD return | -52.34% | -57.34% |
| 1-year return | -78.35% | -80.50% |
| EPS (TTM) | $-0.37 | $-6.74 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $10.00 | $39.00 |
| 52-week low | $0.55 | $3.64 |
| Distance from 52-week high | -92.90% | -81.90% |
| Average volume | 61.46K | 10.03K |
| Shares outstanding | 48.22M | 6.51M |
| Employees | 9 | 18 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Genenta Science S.p.A.
GNTA stock →Genenta Science S.p.A. operates as a strategic consolidator that focuses on acquiring ownership of privately held companies operating in Italian national-security-regulated sectors.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 9 employees
About Tevogen
TVGN stock →Tevogen Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients; and in Phase 1 clinical trial to treat acute SARS-CoV-2 patients with B-cell cancer immune suppression, and other B cell immune suppressed acute SARS-CoV-2 patients with a B cell cancer indication, as well as Long COVID prevention and treatment.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 18 employees
GNTA vs TVGN FAQ
Which is bigger, Genenta Science S.p.A. or Tevogen?
Tevogen (TVGN) is larger, with a market capitalization of $45.97M compared with $34.24M for Genenta Science S.p.A. (GNTA).
Which stock has performed better over the past year, GNTA or TVGN?
GNTA returned -78.35% over the past 12 months, compared with -80.50% for TVGN (price return, excluding dividends). Past performance does not predict future results.
Are Genenta Science S.p.A. and Tevogen in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.